Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Regular insulin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Regular insulin SC at -17 mins |
| 2 | ACTIVE_COMPARATOR | Regular insulin ID at -17 mins |
| 3 | ACTIVE_COMPARATOR | Regular insulin ID at -2 mins |
| 4 | ACTIVE_COMPARATOR | Insulin lispro given SC at -2 mins |
| 5 | EXPERIMENTAL | Insulin lispro given ID at -2 mins |
| Name | Type | Description |
|---|---|---|
| Regular insulin (Humulin) | DRUG | Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days. |
| Insulin lispro (Humalog) | DRUG | Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days. |
Inclusion Criteria: * Type 1 diabetes for 1-15 years, on multiple daily injections (MDI) or insulin pump (CSII) in stable control with HbA1c \<= 9.0%. * Able to attend clinic for 5 different days Exclusion Criteria: * BMI \> 32 kg/m2 * Evidence of gastroparesis or impaired renal function or lipod...
Regular insulin is used for the treatment of Diabetes Mellitus, Type 1. It is an investigational small molecule being studied for its ability to manage blood glucose levels in patients with this condition. The drug is currently in Phase 2 clinical development.
Regular insulin is a form of insulin, which targets insulin receptors to help regulate glucose metabolism. It is being studied for its effects on blood glucose levels after eating in patients with Type 1 diabetes. The drug is administered via intradermal injection.
Regular insulin is being developed by Becton, Dickinson and Company, a company traded on the New York Stock Exchange under the ticker symbol BDX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 1 diabetes.
Regular insulin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its potential use in managing blood glucose levels in patients with Type 1 diabetes.
Regular insulin has one completed clinical trial, identified as NCT00553488. This Phase 2 study, titled 'Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating,' enrolled 30 male participants aged 18 years and older in Germany. The trial was active-controlled and randomized.
Regular insulin is a specific formulation of insulin being developed by Becton, Dickinson and Company. It is administered via intradermal injection, which is a unique delivery method compared to traditional subcutaneous insulin. The drug is currently in Phase 2 trials for Type 1 diabetes.